JP3197651B2 - Skin cosmetics - Google Patents
Skin cosmeticsInfo
- Publication number
- JP3197651B2 JP3197651B2 JP01791093A JP1791093A JP3197651B2 JP 3197651 B2 JP3197651 B2 JP 3197651B2 JP 01791093 A JP01791093 A JP 01791093A JP 1791093 A JP1791093 A JP 1791093A JP 3197651 B2 JP3197651 B2 JP 3197651B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- effect
- test
- whitening
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002537 cosmetic Substances 0.000 title claims description 18
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 claims description 9
- ILKBHIBYKSHTKQ-UHFFFAOYSA-N Diisopropylamine dichloroacetate Chemical compound OC(=O)C(Cl)Cl.CC(C)NC(C)C ILKBHIBYKSHTKQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940084113 diisopropylamine dichloroacetate Drugs 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 description 42
- 238000012360 testing method Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 15
- 230000002087 whitening effect Effects 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- 210000000434 stratum corneum Anatomy 0.000 description 10
- 230000007306 turnover Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 5
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000000245 forearm Anatomy 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000202807 Glycyrrhiza Species 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- -1 aliphatic alcohols Chemical class 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 2
- 229940093767 glabridin Drugs 0.000 description 2
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 229960000990 monobenzone Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、皮膚安全性に優れ、色
黒の皮膚を速やかに淡色化する効果及び角質層のターン
オーバー速度を亢進する効果を有する使用感の優れた皮
膚化粧料に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a skin cosmetic composition which is excellent in skin safety, has an effect of rapidly lightening dark-skinned skin, and an effect of increasing the turnover speed of the stratum corneum, and has an excellent feeling in use. .
【0002】[0002]
【従来の技術及び発明が解決しようとする課題】紫外線
により皮膚は炎症(紅斑)を起こし種々の因子が放出さ
れメラノサイトを刺激する。これにより色調は変化し黒
化する。この黒化は、メラノサイトにおいて産生され表
皮細胞に受け渡されるメラニンの過剰生産が原因であ
り、メラニンはチロシンが酸化されて産生される。2. Description of the Related Art Ultraviolet rays cause inflammation (erythema) on the skin and release various factors to stimulate melanocytes. As a result, the color tone changes and blackens. This darkening is due to overproduction of melanin, which is produced in melanocytes and passed to epidermal cells, and is produced by oxidation of tyrosine.
【0003】従来より、皮膚の黒化やしみ、そばかすを
防ぎ本来の白い肌を保つために、この酸化を防止するビ
タミンCの塩や脂肪酸誘導体、更にハイドロキノンモノ
ベンジルエーテル、過酸化水素等を配合した皮膚化粧料
が提案されている。[0003] Conventionally, in order to prevent skin darkening, spots and freckles and to maintain the original white skin, vitamin C salts and fatty acid derivatives that prevent this oxidation, as well as hydroquinone monobenzyl ether, hydrogen peroxide, etc., are blended. Skin cosmetics have been proposed.
【0004】しかし、これらの美白化粧料中にビタミン
C誘導体を配合すると保存安定性が不充分であるか、紫
外線による炎症抑制効果、美白効果が充分に認められな
いことが多い。一方、美白化粧料中にハイドロキノンモ
ノベンジルエーテル等を配合すると、色黒の肌を淡色化
する効果はあるが、皮膚の安全性上に問題がある等の欠
点がある。この様に、炎症抑制効果、美白効果に優れ且
つ皮膚安全性が高い美白化粧料を得ることは困難を極め
ている。However, when a vitamin C derivative is added to these whitening cosmetics, the storage stability is often insufficient, or the effect of suppressing inflammation and whitening by ultraviolet rays is often not sufficiently recognized. On the other hand, when hydroquinone monobenzyl ether or the like is blended in a whitening cosmetic, it has the effect of lightening dark-skinned skin, but has drawbacks such as a problem in skin safety. As described above, it is extremely difficult to obtain a whitening cosmetic having an excellent anti-inflammatory effect and a whitening effect and having high skin safety.
【0005】また、ジイソプロピルアミンジクロロアセ
テートを単独で配合した場合、角質層のターンオーバー
速度を亢進する効果を有するものの、その美白効果は満
足するものではなかった。Further, when diisopropylamine dichloroacetate alone is blended, it has an effect of increasing the turnover speed of the stratum corneum, but its whitening effect is not satisfactory.
【0006】また、カンゾウの疎水性成分であるグラブ
リジンを単独で配合した場合、抗菌用、抗酸化作用、抗
う触作用、抗プラスミン、メラニン生成抑制作用を有す
ることが確認されている。しかし、美白効果は優れてい
るもののその使用感は満足するものではなかった。It has also been confirmed that glabridine, which is a hydrophobic component of licorice, alone has an antibacterial, antioxidant, anti-antibiotic, antiplasmin, and melanin-suppressing action. However, although the whitening effect was excellent, the feeling of use was not satisfactory.
【0007】[0007]
【課題を解決するための手段】本発明者らは、このよう
な状況に鑑み、従来技術の難点を改良せんとして鋭意研
究を重ねた結果、後記発明が相乗作用によって美白効果
に顕著に優れ、角質層のターンオーバー速度を亢進する
効果を有し且つ皮膚安全性が高く、使用感に優れた皮膚
化粧料となることを見いだし、本発明の完成に至った。Means for Solving the Problems In view of such circumstances, the present inventors have conducted intensive studies to improve the disadvantages of the prior art, and as a result, the invention described later has a remarkably excellent whitening effect by synergism. The present inventors have found that it has an effect of enhancing the turnover speed of the stratum corneum, has high skin safety, and is excellent in a feeling of use, and has completed the present invention.
【0008】即ち、本発明は、美白効果に優れ、且つ皮
膚安全性が高く、角質層のターンオーバー速度を亢進す
る効果を有する使用感に優れた皮膚化粧料を提供するこ
とを目的とするものである。[0008] That is, an object of the present invention is to provide a skin cosmetic composition which is excellent in whitening effect, has high skin safety, and has an effect of enhancing the turnover speed of the stratum corneum and has an excellent feeling in use. It is.
【0009】上記の目的を達成するために、本発明の皮
膚化粧料は次のような構成をとる。即ち、本発明はグラ
ブリジン0.001〜1.0重量%とジイソプロピルア
ミンジクロロアセテート0.01〜1.0重量%とを含
有することを特徴とする皮膚化粧料である。In order to achieve the above object, the skin cosmetic of the present invention has the following constitution. That is, the present invention is a skin cosmetic comprising 0.001 to 1.0% by weight of glabridine and 0.01 to 1.0% by weight of diisopropylamine dichloroacetate.
【0010】本発明の皮膚化粧料に用いられるジイソプ
ロピルアミンジクロロアセテート(以下DADAと略
記)は公知化合物であり、特開昭53−136528に
は、皮膚組織賦活作用を有することが記載されている。[0010] Diisopropylamine dichloroacetate (hereinafter abbreviated as DADA) used in the skin cosmetic of the present invention is a known compound, and JP-A-53-136528 describes that it has a skin tissue activating effect.
【0011】本発明の皮膚化粧料に用いられるグラブリ
ジンは、天然には、甘草の一種であるGlycyrrhiza glab
a Linne var.(通称ロシア・アフガン・トルコカンゾ
ウ)に微量含まれている。グラブリジンの製造法として
は、甘草の根または、その水抽出残渣(例えば、グリチ
ルリチンを抽出した残渣)を有機溶媒で抽出する。抽出
溶媒としては、メタノール、エタノール等の低級脂肪族
アルコール、アセトン等の低級脂肪族ケトン、ジオキサ
ン、エチルエーテル等のエーテル類、塩化メチレン等の
ハロゲン化炭化水素類、酢酸エチル等のエステル類、ヘ
キサン等の炭化水素類の有機溶媒の一種又は2種以上の
混合物を使用することができる。抽出する甘草は、約5
〜15倍量の上記溶媒に浸漬し、常温で静置するか還流
下に加熱する。抽出液から溶媒を留去して得られる抽出
物は、通常5〜10%程度のグラブリジンを含有してい
る。精製は、例えば順相シリカゲルカラムクロマトグラ
フィー及び逆相シリカゲルカラムクロマトグラフィーに
より処理した後、アセトンからの再結晶により比較的容
易にグラブリジンの純品を得ることができる。精製は他
にも合成吸着体によるカラムクロマトグラフィー等の任
意の有機化合物の精製手段を採用して行なうことができ
る。[0011] Glabridin used in the skin cosmetic of the present invention is naturally a kind of licorice, Glycyrrhiza glab.
a A trace amount is contained in Linne var. (commonly known as Russia, Afghanistan and Turkey licorice). As a method for producing grabradine, licorice root or a water-extraction residue thereof (for example, a residue obtained by extracting glycyrrhizin) is extracted with an organic solvent. Examples of the extraction solvent include lower aliphatic alcohols such as methanol and ethanol, lower aliphatic ketones such as acetone, ethers such as dioxane and ethyl ether, halogenated hydrocarbons such as methylene chloride, esters such as ethyl acetate, and hexane. One or a mixture of two or more organic solvents of hydrocarbons such as Liquorice to be extracted is about 5
It is immersed in about 15 times the amount of the above-mentioned solvent and left standing at room temperature or heated under reflux. The extract obtained by distilling off the solvent from the extract usually contains about 5 to 10% of glabridine. Purification can be performed, for example, by normal-phase silica gel column chromatography and reverse-phase silica gel column chromatography, and then a pure glabridine product can be obtained relatively easily by recrystallization from acetone. Purification can be performed by any other means for purifying organic compounds such as column chromatography using a synthetic adsorbent.
【0012】グラブリジンの本発明の皮膚美白化粧料中
への配合量は、総量を基準として、0.001〜1.0
重量%(以下wt%とする)である。[0012] The amount of the skin lightening cosmetic composition of the present invention of Glabridin, based on the total amount, 0. 001-1.0
% By weight (hereinafter referred to as wt%).
【0013】DADAの本発明の皮膚化粧料中への配合
量は、乾燥固形物量で、総量を基準として、0.01〜
1.0wt%である。[0013] The amount of the skin cosmetic of the present invention DADA, on a dry solid amount, based on the total amount, 0. 01 ~
1.0 wt%.
【0014】グラブリジンの配合量が0.001w%未
満で、DADAが0.01w%では本発明の目的とする
効果に充分ではなく、グラブリジン、DADAの配合量
がそれぞれ3.0w%を超えても、その増加分に見合っ
た効果の向上は望めず、使用時の感触が悪くなり易く、
個々の剤型を保持し難くなる。If the amount of glabridine is less than 0.001% by weight and DADA is 0.01% by weight, the effect of the present invention is not sufficient. Even if the amount of glabridine and DADA exceeds 3.0% by weight, respectively. , The improvement of the effect corresponding to the increase cannot be expected, and the feeling at the time of use is likely to deteriorate,
It becomes difficult to hold individual dosage forms.
【0015】本発明の美白化粧料は、常法に従って、ロ
ーション類、乳液類、クリーム類、パック類等の剤型に
することが可能である。The whitening cosmetic composition of the present invention can be made into dosage forms such as lotions, emulsions, creams, packs and the like according to a conventional method.
【0016】尚、本発明の美白化粧料には、色素、香
料、防腐剤、界面活性剤、顔料等を本発明の目的を達成
する範囲で適宜配合することができる。The whitening cosmetic composition of the present invention may be appropriately blended with pigments, fragrances, preservatives, surfactants, pigments and the like within a range that achieves the object of the present invention.
【0017】[0017]
【実施例】以下、実施例及び比較例に基づいて本発明を
詳細に説明する。The present invention will be described below in detail based on examples and comparative examples.
【0018】実施例に記載の(1)チロシナーゼ活性阻
害試験(2)皮膚色明度回復試験(3)美白実用試験
(4)角質層のターンオーバー速度測定試験(5)光パ
ッチ試験(6)官能試験の各試験法は次の通りである。(1) Tyrosinase activity inhibition test (2) Skin color brightness recovery test (3) Whitening practical test (4) Stratum corneum turnover speed measurement test (5) Optical patch test (6) Sensory Each test method is as follows.
【0019】(1)チロシナーゼ活性阻害試験 マックルベイン緩衝液(pH6.8)1mlに0.3m
g/ml濃度のチロシン溶液に各濃度の試料溶液を加
え、37℃にて10分間の予備保温を行う。これに1m
g/ml濃度のチロシナーゼ(シグマ社製)0.1ml
を加え37℃にて15分間加温した後、分光光度計を用
いて、波長475nmにて吸光度(A)を測定した。一
方、チロシナーゼの代わりに緩衝液0.1mlを加えた
ものの吸光度(B)、試料溶液の代わりに緩衝液0.1
ml加えたものの吸光度(C)、更に試料溶液とチロシ
ナーゼの代わりに緩衝液0.2ml加えたものの吸光度
(D)をそれぞれ測定して、下式に従い阻害率(%)を
算出した。(1) Tyrosinase activity inhibition test 0.3 m per 1 ml of McClubine buffer (pH 6.8)
The sample solution of each concentration is added to the tyrosine solution having a concentration of g / ml, and preliminarily kept at 37 ° C. for 10 minutes. 1m to this
0.1 ml of tyrosinase (manufactured by Sigma) at a concentration of g / ml
After heating at 37 ° C. for 15 minutes, the absorbance (A) was measured at a wavelength of 475 nm using a spectrophotometer. On the other hand, the absorbance (B) obtained by adding 0.1 ml of buffer solution instead of tyrosinase,
The absorbance (C) of the solution to which the solution had been added and the absorbance (D) of the solution to which 0.2 ml of the buffer had been added instead of the sample solution and tyrosinase were measured, and the inhibition rate (%) was calculated according to the following formula.
【0020】阻害率(%)={1−(A−B)/(C−
D)} ×100Inhibition rate (%) = {1- (AB) / (C−
D)} × 100
【0021】(2)皮膚色明度回復試験 被試験者20名の上腕内側部皮膚にUVA、UVB領域
の紫外線の最小紅斑量を3日間連続照射して照射終了
後、試料塗布部とベース塗布部皮膚の基準明度(V0
値、V0 ´値)を測定した。引き続いて、1日3回ずつ
4週間連続で塗布し、照射開始1、2、4週間後の試料
塗布部とベース塗布部皮膚の皮膚明度(Vn値、Vn ´
値)を測定して、下記の判定基準により皮膚色の回復評
価を行った。(2) Skin lightness recovery test The skin of the upper inner arm of the 20 test subjects was continuously irradiated with the minimum amount of UVA and UVB erythema in the UVA and UVB regions for 3 days. After the irradiation was completed, the sample application section and the base application section were applied. Reference lightness of skin (V0
(V0 'value) was measured. Subsequently, the composition was applied three times a day for four consecutive weeks, and the skin lightness (Vn value, Vn ′) of the sample-applied part and the base-applied part at 1, 2, and 4 weeks after the start of irradiation
Was measured, and the skin color was evaluated for recovery according to the following criteria.
【0022】尚、皮膚の明度(マンセル表示系V値)は
高速分光色彩計で測定して得られ、X、Y、Z値より算
出した。又、評価は被試験者20名の4週間後の評価点
の平均値で示した。The lightness of the skin (V value of Munsell display system) was obtained by measuring with a high-speed spectral colorimeter and calculated from the X, Y and Z values. The evaluation was shown as an average of the evaluation points of the 20 test subjects after 4 weeks.
【0023】[0023]
【表1】 [Table 1]
【0024】(3)美白実用試験 夏期の太陽光に3時間(1日1.5時間で2日間)曝さ
れた被試験者20名の前腕屈側部皮膚を対象として、左
前腕屈側部皮膚には太陽光に曝された日より、試料を、
右前腕屈側部皮膚には太陽光に曝された日よりベースを
朝夕1回ずつ13週連続塗布した。(3) Practical skin whitening test The left forearm flexing side skin of 20 test subject's forearm flexing side skin exposed to sunlight in summer for 3 hours (1.5 hours a day for 2 days). From the day of sun exposure to the skin,
The base was applied to the right forearm flexion side skin once a day in the morning and evening for 13 weeks from the day of exposure to sunlight.
【0025】尚、評価はベース塗布部より試料塗布部の
効果を確認された被験者の人数で示した。The evaluation was made based on the number of subjects who confirmed the effect of the sample application section from the base application section.
【0026】(4)角質層のターンオーバー速度測定試
験 被験者20名の前腕屈側部皮膚2カ所に1.5MEDの
UVBを1回照射し、3日後に蛍光色素であるダンシル
クロリドを白色ワセリン中に5%wt配合した軟膏を照
射部皮膚に24時間閉塞塗布し、角質層にダンシルクロ
リドを浸透させる。その後、同部位に1日3回(朝、
昼、入浴後)試料とベースを塗布して毎日ダンシルクロ
ライドの蛍光をしらべ、その蛍光が消滅するまでの日数
を調べ、皮膚角質層のターンオーバー速度とした。尚、
通常の皮膚角質層のターンオーバー速度は14〜16日
である。(4) Measurement test of the turnover speed of the stratum corneum Twenty test subjects were irradiated once with 1.5 MED UVB at two sites on the flexion side of the forearm, and three days later, dansyl chloride, a fluorescent dye, was placed in white petrolatum. Ointment mixed with 5% by weight is applied to the irradiated skin for 24 hours, and dansyl chloride is penetrated into the stratum corneum. Then, three times a day (morning,
(After noon, after bathing) The sample and the base were applied, and the fluorescence of dansyl chloride was examined every day. The number of days until the fluorescence disappeared was determined, and the result was defined as the turnover speed of the stratum corneum of the skin. still,
The normal skin stratum corneum turnover rate is 14-16 days.
【0027】(5)光パッチ試験 被験者25名の前腕屈側部皮膚に試料0.05gを塗布
した直径1.0cmのパッチ板を用いて24時間クロー
ズドパッチを行った後、夏期の太陽光を6時間(1日3
時間で2日間)照射した。(5) Optical Patch Test Closed patching was performed for 24 hours using a 1.0 cm diameter patch plate on which 0.05 g of a sample was applied to the skin of the flexed side of the forearm of 25 subjects. 6 hours (3 days a day)
Irradiation for 2 days).
【0028】評価は、下記の判定基準に従い、被験者2
5名の皮膚の状態を評価判定した。判定結果は、照射2
4時間後に、(±)以上の人数で示した。The evaluation was performed according to the following criteria.
The skin condition of five persons was evaluated and evaluated. The judgment result is irradiation 2
Four hours later, the number was indicated by (±) or more.
【0029】[0029]
【表2】 [Table 2]
【0030】(6)官能試験 被験者20名が試料を10日間連用した後の試料の特性
を評価した。(6) Sensory Test Twenty test subjects evaluated the characteristics of the sample after continuously using the sample for 10 days.
【0031】評価は、湿潤性、親和性等のアンケート項
目に対し「皮膚に潤いが生じた」、「皮膚への親和性が
良い」、「皮膚のつやが改善された」と回答した人数で
示した。The evaluation was based on the number of respondents who answered that "skin was moistened", "skin affinity was good", and "skin gloss was improved" in response to questionnaire items such as wettability and affinity. Indicated.
【0032】実施例1〜3、比較例1〜5 二相型ロー
ション 表3の原料組成において、表4に記載の如く有効成分を
配合して、二相型ローションを調製し、前記の諸試験を
実施した。Examples 1 to 3 and Comparative Examples 1 to 5 Two-phase lotion In the raw material composition shown in Table 3, active ingredients were blended as shown in Table 4 to prepare a two-phase lotion. Was carried out.
【0033】[0033]
【表3】 [Table 3]
【0034】[0034]
【表4】 [Table 4]
【0035】(1)調製法 表3に記載のB成分をA成分中に、C成分をD成分中に
均一に溶解した後、A成分とD成分を均一に混合攪拌分
散し次いで容器に充填する。使用時には内容物を均一に
振盪分散して使用する。(1) Preparation method After the components B and C shown in Table 3 are uniformly dissolved in the component A and the component C is uniformly dissolved in the component D, the components A and D are uniformly mixed, stirred and dispersed, and then filled into a container. I do. When used, the contents are shaken and dispersed uniformly.
【0036】(2)特性 諸試験を実施した結果を表4に記載した。表4に示す如
く、比較例1は諸試験において良好な結果は示さなかっ
た。(2) Characteristics Table 4 shows the results of various tests. As shown in Table 4, Comparative Example 1 did not show good results in various tests.
【0037】実施例1〜3の本発明の美白化粧料は諸試
験の総てにおいて明らかに良好な結果を示し、ヒト皮膚
での諸試験において皮膚刺激は生じなかった。The whitening cosmetics of the present invention of Examples 1 to 3 showed clearly good results in all tests and did not cause skin irritation in tests on human skin.
【0038】実施例4〜6、比較例6〜10 スキンク
リーム 表5の原料組成において、表6に記載の如く有効成分を
配合して、スキンクリームを調製し、前記の諸試験を実
施した。Examples 4 to 6 and Comparative Examples 6 to 10 Skin Cream In the raw material composition shown in Table 5, active ingredients were blended as shown in Table 6 to prepare a skin cream, and the above-mentioned tests were carried out.
【0039】[0039]
【表5】 [Table 5]
【0040】[0040]
【表6】 [Table 6]
【0041】(1)調製法 表5に記載のB成分をA成分に混合し、C成分をD成分
にそれぞれ均一に加熱溶解して温度を80℃にする。次
いで、A成分中にD成分を注入乳化した後、攪拌しなが
ら30℃まで冷却する。(1) Preparation method The B component described in Table 5 is mixed with the A component, and the C component is uniformly heated and dissolved in the D component to bring the temperature to 80 ° C. Next, after injecting and emulsifying the D component in the A component, the mixture is cooled to 30 ° C. while stirring.
【0042】諸試験を実施した結果を表6に示した。表
6に示す如く、実施例4〜6は、諸試験の総てにおいて
明らかに良好な結果を示し、ヒト皮膚での諸試験におい
て良好な結果を示し、ヒト皮膚での諸試験において皮膚
刺激は生じなかった。Table 6 shows the results of the tests. As shown in Table 6, Examples 4 to 6 showed clearly good results in all tests, good results in tests on human skin, and skin irritation in tests on human skin. Did not occur.
【0043】以上記載の如く、本発明は、メラニン色素
の産生抑制効果、皮膚の色素沈着を速やかな淡色化効果
及び角質層のターンオーバー速度の亢進効果を有する、
皮膚刺激が無く使用感の優れた皮膚化粧料を提供するこ
とは明らかである。As described above, the present invention has an effect of suppressing the production of melanin pigment, an effect of rapidly lightening skin pigmentation, and an effect of increasing the turnover speed of the stratum corneum.
It is clear that a skin cosmetic composition which is free from skin irritation and has an excellent feeling upon use is provided.
フロントページの続き (56)参考文献 特開 平1−311011(JP,A) 特開 平2−138108(JP,A) 特開 昭64−42414(JP,A) 特開 昭62−96405(JP,A) 特開 昭62−72605(JP,A) 特開 昭61−207312(JP,A) 特開 昭62−96404(JP,A) 特開 昭62−51607(JP,A) (58)調査した分野(Int.Cl.7,DB名) A61K 7/00 - 7/50 CA(STN) REGISTRY(STN)Continuation of front page (56) References JP-A-1-3111011 (JP, A) JP-A-2-138108 (JP, A) JP-A-64-42414 (JP, A) JP-A-62-96405 (JP, A) JP-A-62-72605 (JP, A) JP-A-61-207312 (JP, A) JP-A-62-96404 (JP, A) JP-A-62-51607 (JP, A) (58) Field surveyed (Int. Cl. 7 , DB name) A61K 7/ 00-7/50 CA (STN) REGISTRY (STN)
Claims (1)
ト0.01〜1.0重量%とグラブリジン0.001〜
1.0重量%とを含有することを特徴とする皮膚化粧
料。1. A diisopropylamine dichloroacetate 0.01-1.0 % by weight and glabridine 0.001-0.001.
1. A skin cosmetic comprising 1.0% by weight .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP01791093A JP3197651B2 (en) | 1993-01-08 | 1993-01-08 | Skin cosmetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP01791093A JP3197651B2 (en) | 1993-01-08 | 1993-01-08 | Skin cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06206813A JPH06206813A (en) | 1994-07-26 |
JP3197651B2 true JP3197651B2 (en) | 2001-08-13 |
Family
ID=11956911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP01791093A Expired - Lifetime JP3197651B2 (en) | 1993-01-08 | 1993-01-08 | Skin cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3197651B2 (en) |
-
1993
- 1993-01-08 JP JP01791093A patent/JP3197651B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH06206813A (en) | 1994-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160074316A1 (en) | Topical cosmetic skin lightening compositions and methods of use thereof | |
US8722027B2 (en) | Method for preparing broussonetia kazinoki extract | |
KR20010042530A (en) | Cholesterol Sulfate Compositions for Enhancement of Stratum Corneum Function | |
EP0486595B1 (en) | Use of a coleus extract for skin pigmentation | |
KR101078888B1 (en) | A cosmetic composition comprising tissue cultured Echinaceae adventitious roots and an preparing method thereof | |
JP2986262B2 (en) | Whitening cosmetics | |
JPH1180002A (en) | Preparation for external use for skin preventing aging | |
JP2731329B2 (en) | Skin cosmetics | |
KR100959393B1 (en) | Skin whitening cosmetic composition containing an active ingredient extracted from agar skin and its manufacturing method | |
JP3455406B2 (en) | Skin cosmetics | |
KR102044935B1 (en) | Whitening or moisturizing cosmetic composition comprising the extract of Cicer Arietinum | |
CA2706992C (en) | Topical cosmetic skin lightening compositions and methods of use thereof | |
JP2702860B2 (en) | Skin cosmetics | |
JP3197651B2 (en) | Skin cosmetics | |
JPH06279257A (en) | Melanin biosynthesis inhibitor | |
JP2012509257A (en) | Topical whitening cosmetic composition and method of use | |
KR100678864B1 (en) | Cosmetic composition for skin whitening containing cheongung extract and carnitine as active ingredients | |
KR20030043471A (en) | Cosmetic Compositions Comprising Vitamin C or Derivatives thereof Areca catechu L extract for Preventing Skin Aging | |
JP2942409B2 (en) | Whitening cosmetics | |
KR20080111299A (en) | External preparation composition for skin whitening containing camphorol-3,7-O-alpha-L-diramnopyranoside | |
JP3071293B2 (en) | Whitening cosmetics | |
JP3023249B2 (en) | Whitening cosmetics | |
JPH0710738A (en) | Beautifying cosmetic | |
EP2198848A2 (en) | Compositions comprising self-tanning agents and sugar amines | |
KR20070079390A (en) | Cosmetic composition for skin whitening |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080608 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090608 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090608 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100608 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100608 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110608 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110608 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120608 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120608 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130608 Year of fee payment: 12 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130608 Year of fee payment: 12 |